Appendix 1

Writing Group Disclosures

Writing Group MemberEmploymentResearch GrantOther Research SupportSpeakers’ Bureau/ HonorariaExpert WitnessOwnership InterestConsultant/ Advisory BoardOther
Alexis A. TopjianThe Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine Anesthesia and Critical CareNIH*NoneNonePlaintiff*NoneNoneNone
Dianne AtkinsUniversity of Iowa PediatricsNoneNoneNoneNoneNoneNoneNone
Melissa ChanUniversity of British Columbia Pediatrics BC Children’s HospitalNoneNoneNoneNoneNoneNoneNone
Jonathan P. Duff
  • University of Alberta and Stollery Children’s Hospital

  • Pediatrics

Benny L. Joyner JrUniversity of North Carolina PediatricsNoneNoneNoneNoneNoneNoneNone
Javier J. LasaTexas Children’s Hospital, Baylor College of Medicine Pediatrics/Critical Care Medicine and CardiologyNoneNoneNoneNoneNoneNoneNone
Eric J. LavonasDenver Health Emergency MedicineBTG Pharmaceuticals (Denver Health (Dr Lavonas’ employer) has research, call center, consulting, and teaching agreements with BTG Pharmaceuticals. BTG manufactures the digoxin antidote, DigiFab. Dr Lavonas does not receive bonus or incentive compensation, and these agreements involve an unrelated product. When these guidelines were developed, Dr Lavonas recused from discussions related to digoxin poisoning.)NoneNoneNoneNoneNoneAmerican Heart Association (Senior Science Editor)
Arielle LevyUniversity of Montreal PediatricNoneNoneNoneNoneNoneNoneNone
Melissa MahgoubAmerican Heart AssociationNoneNoneNoneNoneNoneNoneNone
Garth D. MecklerUniversity of British Columbia Pediatrics and Emergency Medicine Ambulatory Care Building, BC Children’sNoneNoneNoneNoneNoneNoneNone
Tia T. RaymondMedical City Children’s Hospital Pediatric Cardiac Intensive Care UnitNoneNoneNoneNoneNoneNoneNone
Kathryn E. RobertsJoe DiMaggio Children’s HospitalNoneNoneNoneNoneNoneNoneNone
Stephen M. SchexnayderUniv. of Arkansas/ Arkansas Children’s Hospital Pediatric Critical CareNoneNoneNoneNoneNoneNoneNone
Robert M. SuttonThe Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine Anesthesia and Critical Care MedicineNIHNoneNoneRoberts & Durkee, Plantiff, 2019NoneNoneNone
  • This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

  • * Modest.

  • Significant.